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Shared Risk
The genetic analysis of 
multifactorial diseases such as 
psoriasis and other immune 
disorders poses a challenge for 
understanding their etiology 
and pathology. Oudot and 
colleagues performed an 
association analysis of 22 
candidate genes that had been 
implicated in skin or immune-
mediated diseases. This 
approach revealed six potential 
psoriasis susceptibility genes 
(FLG, IL1RN, TGM5, CARD15, 
CYLD, and SCLC12A8). This 
study provides support for 
shared genetic factors between 
psoriasis and skin diseases or 
autoimmune disorders and 
lays the foundation for future 
development of individualized 
therapies based on specific 
genetic etiology in psoriasis 




has been implicated as an 
initiating factor for activation 
of pathogenic T cells in the 
inflammatory skin disease 
psoriasis. Cai and colleagues 
demonstrated that T-cell 
activation and IFN-α 
production were diminished 
in psoriatic patients following 
stimulation with streptococcal 
antigen (SA) devoid of 
nucleic acid. Interestingly, this 
activation was reconstituted 
by stimulation with the non–
nucleic acid SA combined with 
the immunostimulatory CpG-A 
motif. These results specifically 
implicate streptococcal DNA 
in the pathogenic immune 
reaction following streptococcal 
infection in psoriasis patients. 
See page 2653
AMPed-Up Response Against Vaccinia
Historically, vaccinia virus (VV) has been 
used to immunize against smallpox; however, 
adverse reactions such as progressive vaccinia 
and eczema vaccinatum may occur in indi-
viduals with immunodeficiencies or other skin 
disorders, probably as a result of a deficiency 
in antimicrobial peptides (AMPs) in these 
individuals. Ceragenins (CSAs) are a new class 
of synthetic compounds designed to mimic 
AMPs and disrupt bacterial membranes. Howell et al. report that CSA-13 exhibited 
potent antiviral activity against VV, rescued infected cells in vitro via targeting of 
viral envelopes, and induced the expression of AMPs LL-37 and HBD-3. CSA-13 
also reduced development of lesions and inhibited VV replication in mice. With the 
threat of smallpox as a biological weapon, orthopoxvirus treatment options, such as 
these new AMP mimics, are important. See page 2668
New Histamine Blocker
The most common method for treating mast cell 
(MC)-driven diseases, such as allergic rhinitis or 
urticaria, uses H1-antihistamines, although it has 
been suggested that MC stabilizers that inhibit 
MC activation and inflammatory molecule release 
might provide further benefit. Indeed, Weller and 
Maurer demonstrated that the second-generation 
antihistamine desloratadine inhibited activation 
of human skin MCs and subsequent histamine 
release. Thus, this drug is an effective MC stabi-
lizer in vitro and may be valuable for treating 
MC-mediated diseases of the skin. See page 2723
To Advance a T-Cell Invasion
Squamous cell carcinoma (SCC) devel-
ops in transplant recipients as a result 
of medications that suppress effector 
T-cell function and, consequently, allow 
increased regulatory T-cell function. 
Treatment with imiquimod reversed this 
effect. Huang and colleagues showed that 
imiquimod-treated SCCs are infiltrated by 
CD8+ T cells that result in tumor regres-
sion, and that production of the antitumor 
molecules IFN-γ, perforin, and granzyme 
is enhanced in these T cells. In addition, 
following treatment, nonregulatory T cells 
produce less of the immunosuppressive 
cytokines IL-1 and transforming growth 
factor-β. Together, these results support the use of imiquimod as an adjunctive 
therapy with surgery or for immunosuppressed patients who are poor surgical 
candidates. See page 2676
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